100 related articles for article (PubMed ID: 15535431)
1. LAF-237 (Novartis).
Barlocco D
Curr Opin Investig Drugs; 2004 Oct; 5(10):1094-100. PubMed ID: 15535431
[TBL] [Abstract][Full Text] [Related]
2. Dipeptidyl peptidase IV inhibitors for the treatment of diabetes.
Weber AE
J Med Chem; 2004 Aug; 47(17):4135-41. PubMed ID: 15293982
[No Abstract] [Full Text] [Related]
3. Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications.
Ahrén B
Diabetes Care; 2007 Jun; 30(6):1344-50. PubMed ID: 17337494
[No Abstract] [Full Text] [Related]
4. [Sitagliptin. DPP-4 inhibitors as a useful extension of oral diabetes therapy?].
Matthes J; Faust M
Dtsch Med Wochenschr; 2008 Oct; 133(43):2233-7. PubMed ID: 18924057
[No Abstract] [Full Text] [Related]
5. [Dipeptidylpeptidase IV inhibitors and dual action PPAR-agonists].
Heinzl S
Med Monatsschr Pharm; 2006 Mar; 29(3):93-6. PubMed ID: 16550882
[No Abstract] [Full Text] [Related]
6. The role of vildagliptin in the management of type 2 diabetes mellitus.
Kleppinger EL; Helms K
Ann Pharmacother; 2007 May; 41(5):824-32. PubMed ID: 17456545
[TBL] [Abstract][Full Text] [Related]
7. Vildagliptin in clinical practice: a review of literature.
Banerjee M; Younis N; Soran H
Expert Opin Pharmacother; 2009 Nov; 10(16):2745-57. PubMed ID: 19874253
[TBL] [Abstract][Full Text] [Related]
8. Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Augeri DJ; Robl JA; Betebenner DA; Magnin DR; Khanna A; Robertson JG; Wang A; Simpkins LM; Taunk P; Huang Q; Han SP; Abboa-Offei B; Cap M; Xin L; Tao L; Tozzo E; Welzel GE; Egan DM; Marcinkeviciene J; Chang SY; Biller SA; Kirby MS; Parker RA; Hamann LG
J Med Chem; 2005 Jul; 48(15):5025-37. PubMed ID: 16033281
[TBL] [Abstract][Full Text] [Related]
9. DPP-4 inhibitors and their potential role in the management of type 2 diabetes.
Barnett A
Int J Clin Pract; 2006 Nov; 60(11):1454-70. PubMed ID: 17073841
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by Vildagliptin ((2S)-{[(3-hydroxyadamantan-1-yl)amino]acetyl}-pyrrolidine-2-carbonitrile).
Brandt I; Joossens J; Chen X; Maes MB; Scharpé S; De Meester I; Lambeir AM
Biochem Pharmacol; 2005 Jul; 70(1):134-43. PubMed ID: 15907807
[TBL] [Abstract][Full Text] [Related]
11. 7-But-2-ynyl-9-(6-methoxy-pyridin-3-yl)-6-piperazin-1-yl-7,9-dihydro-purin-8-one is a novel competitive and selective inhibitor of dipeptidyl peptidase IV with an antihyperglycemic activity.
Yamazaki K; Yasuda N; Inoue T; Nagakura T; Kira K; Shinoda M; Saeki T; Tanaka I
J Pharmacol Exp Ther; 2006 Dec; 319(3):1253-7. PubMed ID: 16980568
[TBL] [Abstract][Full Text] [Related]
12. From the bench to the bedside: dipeptidyl peptidase IV inhibitors, a new class of oral antihyperglycemic agents.
Pei Z
Curr Opin Drug Discov Devel; 2008 Jul; 11(4):512-32. PubMed ID: 18600568
[TBL] [Abstract][Full Text] [Related]
13. Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus.
Langley AK; Suffoletta TJ; Jennings HR
Pharmacotherapy; 2007 Aug; 27(8):1163-80. PubMed ID: 17655515
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes.
Rosenstock J; Kim SW; Baron MA; Camisasca RP; Cressier F; Couturier A; Dejager S
Diabetes Obes Metab; 2007 Mar; 9(2):175-85. PubMed ID: 17300593
[TBL] [Abstract][Full Text] [Related]
15. 1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties.
Villhauer EB; Brinkman JA; Naderi GB; Burkey BF; Dunning BE; Prasad K; Mangold BL; Russell ME; Hughes TE
J Med Chem; 2003 Jun; 46(13):2774-89. PubMed ID: 12801240
[TBL] [Abstract][Full Text] [Related]
16. (3R,4S)-4-(2,4,5-Trifluorophenyl)-pyrrolidin-3-ylamine inhibitors of dipeptidyl peptidase IV: synthesis, in vitro, in vivo, and X-ray crystallographic characterization.
Wright SW; Ammirati MJ; Andrews KM; Brodeur AM; Danley DE; Doran SD; Lillquist JS; Liu S; McClure LD; McPherson RK; Olson TV; Orena SJ; Parker JC; Rocke BN; Soeller WC; Soglia CB; Treadway JL; Vanvolkenburg MA; Zhao Z; Cox ED
Bioorg Med Chem Lett; 2007 Oct; 17(20):5638-42. PubMed ID: 17822893
[TBL] [Abstract][Full Text] [Related]
17. [Sitagliptin. Dipeptidylpeptidase 4 inhibitor for patients with diabetes mellitus type 2].
Musch A; Heinzl S
Med Monatsschr Pharm; 2007 Aug; 30(8):282-6; quiz 287-8. PubMed ID: 17879807
[No Abstract] [Full Text] [Related]
18. Combination of dipeptidylpeptidase IV inhibitor and low dose thiazolidinedione: preclinical efficacy and safety in db/db mice.
Roy S; Khanna V; Mittra S; Dhar A; Singh S; Mahajan DC; Priyadarsiny P; Davis JA; Sattigeri J; Saini KS; Bansal VS
Life Sci; 2007 Jun; 81(1):72-9. PubMed ID: 17532347
[TBL] [Abstract][Full Text] [Related]
19. Saxagliptin, a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Gallwitz B
IDrugs; 2008 Dec; 11(12):906-17. PubMed ID: 19051153
[TBL] [Abstract][Full Text] [Related]
20. Effect of vildagliptin on glucagon concentration during meals in patients with type 1 diabetes.
Foley JE; Ligueros-Saylan M; He YL; Holst JJ; Deacon CF; Dunning BE; Leone-Jones A; Yu T; Kelley DE
Horm Metab Res; 2008 Oct; 40(10):727-30. PubMed ID: 18597213
[No Abstract] [Full Text] [Related]
[Next] [New Search]
